Table 6.
Multivariate logistic regression analysis on response to cyclophosphamide therapy considering CYP2B6 genetic polymorphisms, estimated phenotypes and non-genetic factors (age, sex).
| Models | Variables | Response to therapy | ||
|---|---|---|---|---|
| Coefficient B (SE) | Exp ß | P value | ||
| SNVs, non-genetic factorsa,e | Constant | 23.31 (40,192) | 1.338E+10 | 1.00 |
| g.-82T>C (rs34223104) | − 22.11 (40,192) | 0.00 | 1.00 | |
| g.15631G>T (rs3745274) | 0.29 (1.47) | 1.34 | 0.83 | |
| Model 1 (corrected P ≤ 0.01) | g.18053A>G (rs2279343) | 0.45 (1.45) | 1.58 | 0.75 |
| g.25505C>T (rs3211371) | 0.38 (0.9) | 1.46 | 0.67 | |
| Sex | − 1.5 (0.72) | 0.22 | 0.03 | |
| Age | − 0.75 (0.74) | 0.17 | 0.01 | |
| Haplotypesd, non-genetic factorsb,e | Constant | 21.83 (40,192) | 3,041,354,571 | 1.00 |
| CYP2B6*4 (g.-82T/15631G/18053G/25505C) | 1.39 (1.22) | 4.01 | 0.25 | |
| CYP2B6*5 (g.-82T/15631G/18053A/25505T) | 0.52 (0.91) | 1.68 | 0.56 | |
| Model 2 (corrected P ≤ 0.02) | CYP2B6*6 (g.-82T/15631T/18053G/25505T) | 0.73 (0.73) | 2.08 | 0.32 |
| CYP2B6*22 (g.-82C/15631G/18053A/25505C) | − 21.99 (40,192) | 0.00 | 1.00 | |
| Sex | − 1.57 (0.73) | 0.20 | 0.03 | |
| Age | − 1.7 (0.75) | 0.18 | 0.02 | |
| Estimated phenotype, non-genetic factorsc,e | Constant | − 1.39 (0.77) | 0.24 | 0.07 |
| Poor/intermediate | − 0.69 (0.68) | 0.49 | 0.3 | |
| Model 3 (corrected P ≤ 0.02) | Sex | 1.36 (0.69) | 3.89 | 0.04 |
| Age | 1.58 (0.71) | 4.86 | 0.02 | |
Significant values are in bold.
aAIC: 41.63, BIC: 54.72 for model 1, bAIC: 44.11, BIC: 57.21 for model 2, cAIC: 25.46, BIC: 32.94, dIn haplotypes, the polymorphic variants were indicated in bold. ePost-hoc power: 57.0%.